{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpCreated=2018-03-14T20%3A49%3A11.740Z&answeringDeptId=29&max-ddpModified.=2018-03-06T13%3A05%3A17.356Z&min-date=2017-11-27&min-ddpModified.=2018-02-05T17%3A56%3A01.934Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?max-ddpCreated=2018-03-14T20%3A49%3A11.740Z&answeringDeptId=29&max-ddpModified.=2018-03-06T13%3A05%3A17.356Z&min-date=2017-11-27&min-ddpModified.=2018-02-05T17%3A56%3A01.934Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpCreated=2018-03-14T20%3A49%3A11.740Z&answeringDeptId=29&max-ddpModified.=2018-03-06T13%3A05%3A17.356Z&min-date=2017-11-27&_metadata=all&min-ddpModified.=2018-02-05T17%3A56%3A01.934Z", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&max-ddpCreated=2018-03-14T20%3A49%3A11.740Z&answeringDeptId=29&max-ddpModified.=2018-03-06T13%3A05%3A17.356Z&min-date=2017-11-27&min-ddpModified.=2018-02-05T17%3A56%3A01.934Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpCreated=2018-03-14T20%3A49%3A11.740Z&answeringDeptId=29&max-ddpModified.=2018-03-06T13%3A05%3A17.356Z&min-date=2017-11-27&min-ddpModified.=2018-02-05T17%3A56%3A01.934Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpCreated=2018-03-14T20%3A49%3A11.740Z&answeringDeptId=29&max-ddpModified.=2018-03-06T13%3A05%3A17.356Z&min-date=2017-11-27&min-ddpModified.=2018-02-05T17%3A56%3A01.934Z", "items" : [{"_about" : "http://data.parliament.uk/resources/855493", "AnsweringBody" : [{"_value" : "Department for Work and Pensions"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/855493/answer", "answerText" : {"_value" : "
The information requested is shown in the table below.<\/p>
<\/p>
Number of Employment and Support Allowance (ESA) claimants with at least one work capability assessment outcome, with a main disabling condition of Cystic Fibrosis, Motor Neurone Disease, Multiple Sclerosis, Parkinson\u2019s Disease or Rheumatoid Arthritis, by assessment type, assessment outcome and year 20082<\/sup> to 20174<\/sup>, Great Britain<\/strong><\/p> <\/strong><\/p><\/td> <\/strong><\/p><\/td> \u2018000s<\/em><\/strong><\/p><\/td><\/tr> Condition<\/strong><\/p><\/td> Year of completed assessment<\/strong><\/p><\/td><\/tr> Assessment type - Outcome<\/p><\/td> 08<\/strong><\/p><\/td> 09<\/strong><\/p><\/td> 10<\/strong><\/p><\/td> 11<\/strong><\/p><\/td> 12<\/strong><\/p><\/td> 13<\/strong><\/p><\/td> 14<\/strong><\/p><\/td> 15<\/strong><\/p><\/td> 16<\/strong><\/p><\/td> 17<\/strong><\/p><\/td> Total<\/strong><\/p><\/td><\/tr> Cystic Fibrosis<\/strong><\/p><\/td><\/tr> Initial - Support Group<\/p><\/td> -<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.2<\/p><\/td> 0.1<\/p><\/td> 0.2<\/p><\/td> 0.2<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 1.0<\/strong><\/p><\/td><\/tr> Initial - WRAG<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.1<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.1<\/strong><\/p><\/td><\/tr> Initial - Fit for Work<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.1<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.1<\/strong><\/p><\/td><\/tr> Repeat - Support Group<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> -<\/p><\/td> 0.2<\/p><\/td> 0.1<\/p><\/td> 0.6<\/strong><\/p><\/td><\/tr> Repeat - WRAG<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.1<\/strong><\/p><\/td><\/tr> Repeat - Fit For Work<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/strong><\/p><\/td><\/tr> IBR - Support Group<\/p><\/td> .<\/p><\/td> .<\/p><\/td> .<\/p><\/td> 0.1<\/p><\/td> 0.2<\/p><\/td> 0.3<\/p><\/td> 0.1<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.6<\/strong><\/p><\/td><\/tr> IBR - WRAG<\/p><\/td> .<\/p><\/td> .<\/p><\/td> .<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.1<\/strong><\/p><\/td><\/tr> IBR - Fit for Work<\/p><\/td> .<\/p><\/td> .<\/p><\/td> .<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/strong><\/p><\/td><\/tr> Motor Neurone Disease<\/strong><\/p><\/td><\/tr> Initial - Support Group<\/p><\/td> -<\/p><\/td> 0.1<\/p><\/td> 0.2<\/p><\/td> 0.2<\/p><\/td> 0.2<\/p><\/td> 0.2<\/p><\/td> 0.2<\/p><\/td> 0.2<\/p><\/td> 0.2<\/p><\/td> 0.1<\/p><\/td> 1.5<\/strong><\/p><\/td><\/tr> Initial - WRAG<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.1<\/strong><\/p><\/td><\/tr> Initial - Fit for Work<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/strong><\/p><\/td><\/tr> Repeat - Support Group<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.1<\/p><\/td> -<\/p><\/td> 0.3<\/strong><\/p><\/td><\/tr> Repeat - WRAG<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/strong><\/p><\/td><\/tr> Repeat - Fit For Work<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/strong><\/p><\/td><\/tr> IBR - Support Group<\/p><\/td> .<\/p><\/td> .<\/p><\/td> .<\/p><\/td> -<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.2<\/strong><\/p><\/td><\/tr> IBR - WRAG<\/p><\/td> .<\/p><\/td> .<\/p><\/td> .<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/strong><\/p><\/td><\/tr> IBR - Fit for Work<\/p><\/td> .<\/p><\/td> .<\/p><\/td> .<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/strong><\/p><\/td><\/tr> Multiple Sclerosis<\/strong><\/p><\/td><\/tr> Initial - Support Group<\/p><\/td> -<\/p><\/td> 0.5<\/p><\/td> 0.7<\/p><\/td> 0.9<\/p><\/td> 1.5<\/p><\/td> 1.3<\/p><\/td> 1.8<\/p><\/td> 1.5<\/p><\/td> 1.1<\/p><\/td> 0.7<\/p><\/td> 9.7<\/strong><\/p><\/td><\/tr> Initial - WRAG<\/p><\/td> -<\/p><\/td> 0.7<\/p><\/td> 0.9<\/p><\/td> 0.5<\/p><\/td> 0.3<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> -<\/p><\/td> 2.8<\/strong><\/p><\/td><\/tr> Initial - Fit for Work<\/p><\/td> -<\/p><\/td> 0.4<\/p><\/td> 0.4<\/p><\/td> 0.3<\/p><\/td> 0.3<\/p><\/td> 0.2<\/p><\/td> 0.1<\/p><\/td> 0.2<\/p><\/td> 0.3<\/p><\/td> 0.1<\/p><\/td> 2.2<\/strong><\/p><\/td><\/tr> Repeat - Support Group<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.2<\/p><\/td> 0.8<\/p><\/td> 2<\/p><\/td> 2<\/p><\/td> 1.8<\/p><\/td> 0.4<\/p><\/td> 3.7<\/p><\/td> 1.1<\/p><\/td> 9.7<\/strong><\/p><\/td><\/tr> Repeat - WRAG<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.4<\/p><\/td> 0.6<\/p><\/td> 0.7<\/p><\/td> 0.3<\/p><\/td> 0.1<\/p><\/td> -<\/p><\/td> 0.1<\/p><\/td> -<\/p><\/td> 1.7<\/strong><\/p><\/td><\/tr> Repeat - Fit For Work<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.5<\/strong><\/p><\/td><\/tr> IBR - Support Group<\/p><\/td> .<\/p><\/td> .<\/p><\/td> .<\/p><\/td> 1.4<\/p><\/td> 4.2<\/p><\/td> 7<\/p><\/td> 2.3<\/p><\/td> 0.7<\/p><\/td> 0.5<\/p><\/td> 0.1<\/p><\/td> 16.2<\/strong><\/p><\/td><\/tr> IBR - WRAG<\/p><\/td> .<\/p><\/td> .<\/p><\/td> .<\/p><\/td> 0.5<\/p><\/td> 1.1<\/p><\/td> 0.9<\/p><\/td> 0.1<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 2.6<\/strong><\/p><\/td><\/tr> IBR - Fit for Work<\/p><\/td> .<\/p><\/td> .<\/p><\/td> .<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.3<\/strong><\/p><\/td><\/tr> Parkinsons Disease<\/strong><\/p><\/td><\/tr> Initial - Support Group<\/p><\/td> -<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.2<\/p><\/td> 0.3<\/p><\/td> 0.3<\/p><\/td> 0.4<\/p><\/td> 0.4<\/p><\/td> 0.2<\/p><\/td> 0.2<\/p><\/td> 2.1<\/strong><\/p><\/td><\/tr> Initial - WRAG<\/p><\/td> -<\/p><\/td> 0.2<\/p><\/td> 0.3<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.8<\/strong><\/p><\/td><\/tr> Initial - Fit for Work<\/p><\/td> -<\/p><\/td> 0.2<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.8<\/strong><\/p><\/td><\/tr> Repeat - Support Group<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.1<\/p><\/td> 0.3<\/p><\/td> 0.3<\/p><\/td> 0.2<\/p><\/td> 0.1<\/p><\/td> 0.4<\/p><\/td> 0.1<\/p><\/td> 1.3<\/strong><\/p><\/td><\/tr> Repeat - WRAG<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.1<\/p><\/td> 0.2<\/p><\/td> 0.2<\/p><\/td> 0.1<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.4<\/strong><\/p><\/td><\/tr> Repeat - Fit For Work<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.1<\/strong><\/p><\/td><\/tr> IBR - Support Group<\/p><\/td> .<\/p><\/td> .<\/p><\/td> .<\/p><\/td> 0.1<\/p><\/td> 0.3<\/p><\/td> 0.6<\/p><\/td> 0.2<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 1.3<\/strong><\/p><\/td><\/tr> IBR - WRAG<\/p><\/td> .<\/p><\/td> .<\/p><\/td> .<\/p><\/td> -<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.3<\/strong><\/p><\/td><\/tr> IBR - Fit for Work<\/p><\/td> .<\/p><\/td> .<\/p><\/td> .<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/strong><\/p><\/td><\/tr> Rheumatoid Arthritis<\/strong><\/p><\/td><\/tr> Initial - Support Group<\/p><\/td> -<\/p><\/td> 0.2<\/p><\/td> 0.2<\/p><\/td> 0.3<\/p><\/td> 0.6<\/p><\/td> 0.6<\/p><\/td> 1.0<\/p><\/td> 0.9<\/p><\/td> 0.5<\/p><\/td> 0.3<\/p><\/td> 4.5<\/strong><\/p><\/td><\/tr> Initial - WRAG<\/p><\/td> -<\/p><\/td> 0.7<\/p><\/td> 0.9<\/p><\/td> 0.6<\/p><\/td> 0.6<\/p><\/td> 0.3<\/p><\/td> 0.2<\/p><\/td> 0.2<\/p><\/td> 0.2<\/p><\/td> 0.1<\/p><\/td> 3.7<\/strong><\/p><\/td><\/tr> Initial - Fit for Work<\/p><\/td> -<\/p><\/td> 0.8<\/p><\/td> 0.9<\/p><\/td> 0.6<\/p><\/td> 0.7<\/p><\/td> 0.5<\/p><\/td> 0.3<\/p><\/td> 0.6<\/p><\/td> 0.6<\/p><\/td> 0.3<\/p><\/td> 5.2<\/strong><\/p><\/td><\/tr> Repeat - Support Group<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.1<\/p><\/td> 0.3<\/p><\/td> 0.8<\/p><\/td> 1.4<\/p><\/td> 1.5<\/p><\/td> 0.4<\/p><\/td> 1.9<\/p><\/td> 0.8<\/p><\/td> 5.9<\/strong><\/p><\/td><\/tr> Repeat - WRAG<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.4<\/p><\/td> 0.8<\/p><\/td> 1.2<\/p><\/td> 0.8<\/p><\/td> 0.4<\/p><\/td> 0.1<\/p><\/td> 0.2<\/p><\/td> 0.1<\/p><\/td> 3<\/strong><\/p><\/td><\/tr> Repeat - Fit For Work<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.1<\/p><\/td> 0.3<\/p><\/td> 0.3<\/p><\/td> 0.2<\/p><\/td> 0.2<\/p><\/td> 0.1<\/p><\/td> 0.4<\/p><\/td> 0.2<\/p><\/td> 1.7<\/strong><\/p><\/td><\/tr> IBR - Support Group<\/p><\/td> .<\/p><\/td> .<\/p><\/td> .<\/p><\/td> 0.5<\/p><\/td> 1.5<\/p><\/td> 2.6<\/p><\/td> 1.1<\/p><\/td> 0.5<\/p><\/td> 0.3<\/p><\/td> 0.1<\/p><\/td> 6.6<\/strong><\/p><\/td><\/tr> IBR - WRAG<\/p><\/td> .<\/p><\/td> .<\/p><\/td> .<\/p><\/td> 0.8<\/p><\/td> 2.2<\/p><\/td> 1.7<\/p><\/td> 0.3<\/p><\/td> 0.1<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 5<\/strong><\/p><\/td><\/tr>